CA3134801A1 - Gepotidacine destine a etre utilise dans le traitement d'infections bacteriennes des voies urinaires - Google Patents

Gepotidacine destine a etre utilise dans le traitement d'infections bacteriennes des voies urinaires Download PDF

Info

Publication number
CA3134801A1
CA3134801A1 CA3134801A CA3134801A CA3134801A1 CA 3134801 A1 CA3134801 A1 CA 3134801A1 CA 3134801 A CA3134801 A CA 3134801A CA 3134801 A CA3134801 A CA 3134801A CA 3134801 A1 CA3134801 A1 CA 3134801A1
Authority
CA
Canada
Prior art keywords
streptococcus
staphylococcus
gepotidacin
uti
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3134801A
Other languages
English (en)
Inventor
David John Payne
Stephen Rittenhouse
Nicole SCANGARELLA-OMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxomithkline Intellectual Property Development Ltd
Original Assignee
Glaxomithkline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxomithkline Intellectual Property Development Ltd filed Critical Glaxomithkline Intellectual Property Development Ltd
Publication of CA3134801A1 publication Critical patent/CA3134801A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des composés destinés à être utilisés pour traiter une infection des voies urinaires, comprenant l'administration de gépotidacine ou d'un sel pharmaceutiquement acceptable de celui-ci, dans une quantité thérapeutiquement efficace chez un être humain en ayant besoin, l'infection des voies urinaires étant provoquée par une ou plusieurs bactéries telles que définies dans la description.
CA3134801A 2019-04-03 2020-04-03 Gepotidacine destine a etre utilise dans le traitement d'infections bacteriennes des voies urinaires Pending CA3134801A1 (fr)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962828801P 2019-04-03 2019-04-03
US62/828,801 2019-04-03
US201962834112P 2019-04-15 2019-04-15
US62/834,112 2019-04-15
US201962841384P 2019-05-01 2019-05-01
US201962841363P 2019-05-01 2019-05-01
US201962841375P 2019-05-01 2019-05-01
US62/841,384 2019-05-01
US62/841,363 2019-05-01
US62/841,375 2019-05-01
US201962895601P 2019-09-04 2019-09-04
US201962895594P 2019-09-04 2019-09-04
US201962895590P 2019-09-04 2019-09-04
US62/895,594 2019-09-04
US62/895,601 2019-09-04
US62/895,590 2019-09-04
PCT/IB2020/000261 WO2020201833A1 (fr) 2019-04-03 2020-04-03 Gépotidacine destiné à être utilisé dans le traitement d'infections bactériennes des voies urinaires

Publications (1)

Publication Number Publication Date
CA3134801A1 true CA3134801A1 (fr) 2020-10-08

Family

ID=70861514

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3134801A Pending CA3134801A1 (fr) 2019-04-03 2020-04-03 Gepotidacine destine a etre utilise dans le traitement d'infections bacteriennes des voies urinaires

Country Status (6)

Country Link
EP (1) EP3946342A1 (fr)
JP (2) JP2022528890A (fr)
CN (1) CN114828854A (fr)
BR (1) BR112021018815A2 (fr)
CA (1) CA3134801A1 (fr)
WO (1) WO2020201833A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3210313A1 (fr) 2021-02-05 2022-08-11 Glaxosmithkline Intellectual Property Development Limited Formulations en doses solides administrees par voie orale
CN118574619A (zh) * 2022-01-21 2024-08-30 葛兰素史密斯克莱知识产权发展有限公司 吉泊达星和万古霉素用于治疗由腐生葡萄球菌引起的感染
EP4316463A1 (fr) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Nouvelle formule
JP2025532252A (ja) 2022-09-26 2025-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 処置方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001097863A (ja) * 1999-09-24 2001-04-10 Smithkline Beecham Corp 嫌気性病原菌に対するフルオロキノロン化合物の使用法
NZ579877A (en) * 2007-04-20 2011-09-30 Glaxo Group Ltd Tricyclic nitrogen containing compounds as antibacterial agents
CA2958800C (fr) * 2014-08-22 2020-10-27 Glaxosmithkline Intellectual Property Development Limited Composes contenant de l'azote tricyclique pour le traitement de l'infection a neisseria gonorrhoeae

Also Published As

Publication number Publication date
EP3946342A1 (fr) 2022-02-09
WO2020201833A1 (fr) 2020-10-08
JP2025084772A (ja) 2025-06-03
CN114828854A (zh) 2022-07-29
WO2020201833A8 (fr) 2022-08-04
BR112021018815A2 (pt) 2022-03-03
JP2022528890A (ja) 2022-06-16

Similar Documents

Publication Publication Date Title
JP2025084772A (ja) 細菌性尿路感染症の治療に使用するためのゲポチダシン
CN113015532B (zh) 包含β-内酰胺酶抑制剂的组合式组合物
BR112017010132B1 (pt) Combinações e seus usos no tratamento de infecções bacterianas resistentes
CZ288984B6 (cs) Farmaceutický prostředek k inhibici Alzheimerovy nemoci, ke zvyąování TGF-beta exprese v mozku, k inhibici zánětlivé odezvy spojené s Alzheimerovou nemocí a k inhibici neurotoxicity zprostředkované beta-amyloidním peptidem
US20210137948A1 (en) Treatment of infections caused by neisseria gonococcus using a halogenated salicylanilide
Galgiani et al. Bacteroides fragilis endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole
EP3993796B1 (fr) Combinaison pour le traitement des infections causées par mycoplasma genitalium
JP7466544B2 (ja) テトラサイクリン化合物を使用してマイコバクテリア感染症を処置する方法
US20230398139A1 (en) Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections
Arshad et al. Comparative in vitro antibacterial analysis of different brands of cefixime against clinical isolates of Staphylococcus aureus and Escherichia coli
US6274595B1 (en) Compositions for treating infection using optically pure (S)-lomefloxacin
US20220184071A1 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
Kassab DEVELOPMENT OF NOVEL ANTIMICROBIAL TETRACYCLINE ANALOG B (IODOCYCLINE) BY CHEMO-INFORMATICS.
US20250099535A1 (en) Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus
EP4491231A2 (fr) Posologie pour traiter une infection à neisseria gonorrhoeae avec de la gépotidacine
CN106659718A (zh) 包含抗菌剂的药物组合物
US20210308131A1 (en) Treatment Regimen
WO2001021176A1 (fr) Procedes d'utilisation de composes de fluoroquinolone contre les bacteries
JP2025532252A (ja) 処置方法
EP3294317B1 (fr) Composition antibiotique améliorée
Richard Cystitis in women treatment with levofloxacin preparations. Application of levofloxacin in urological practice
PT661974E (pt) Metodos e composicoes para o tratamento de infeccao utilizando (r)-lomefloxacina opticamente pura

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240318

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250319

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250320

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250422

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250714

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250728

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250728

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250904

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260319

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260401

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260401